Emilien Billon
Research Subjects
Emilien Billon has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Olive
Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University UM105 and Paoli-Calmettes Institute, Marseille, France
34 shared publications - Laurent Gorvel
Immunity and Cancer Team, Cancer Research Center of Marseille, CRCM, INSERM U1068, CNRS UMR7258, Aix-Marseille University U105, Marseille, France
34 shared publications - Amira Ben Amara
Team Immunity and Cancer, Centre de Recherche en Cancerologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli–Calmettes, Aix–Marseille University, UM105, Marseille, France
33 shared publications - Anne-Sophie Chrétien
Immunomonitoring Platform, Cancer Research Center of Marseille, CRCM, INSERM U1068, CNRS UMR7258, Aix-Marseille University U105, Marseille, France
33 shared publications - Jacques A. Nunes
Centre de Recherche en Cancérologie de Marseille
33 shared publications - Marie-Sarah Rouvière
Team Immunity and Cancer, Centre de Recherche en Cancerologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli–Calmettes, Aix–Marseille University, UM105, Marseille, France
33 shared publications
Latest Publications
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer
To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer
To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Supplementary Figure 3: MFA individual parameters and immune cell enrichment-related survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Supplementary Figure 3: MFA individual parameters and immune cell enrichment-related survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Lymphoid cells staining panel for mass cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Lymphoid cells staining panel for mass cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Cell enrichment analysis output table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Cell enrichment analysis output table
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Myeloid cell staining panel for mass cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Myeloid cell staining panel for mass cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Supplementary Figure 4: Multivariate analysis of cervical cancer patient clinical and TLS parameters.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Supplementary Figure 4: Multivariate analysis of cervical cancer patient clinical and TLS parameters.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Primary antibodies used in IHF
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Primary antibodies used in IHF
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Supplementary Table S9 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer
Supplementary Table S9 from Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer